# Gemcitabine/Cisplatin +/-Cetuximab in Patients With Locally Advanced or Metastatic EGFR-Positive Pancreatic Cancer

> **NCT00536614** · PHASE2 · COMPLETED · sponsor: **Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente** · enrollment: 86 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **GENETIC:** cetuximab

## Key facts

- **NCT ID:** NCT00536614
- **Lead sponsor:** Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** —
- **Final completion:** 2006-09
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2007-09-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00536614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00536614, "Gemcitabine/Cisplatin +/-Cetuximab in Patients With Locally Advanced or Metastatic EGFR-Positive Pancreatic Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00536614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*